Literature DB >> 14551719

New long-acting androgens.

Louis J Gooren1.   

Abstract

Testosterone substitution treatment aims to replace physiological actions of endogenous testosterone by steadily maintaining physiological blood levels of testosterone. The underlying conditions rendering androgen replacement necessary are usually irreversible. The consequence is that almost life-long androgen replacement is required. Patient compliance with life-long androgen replacement depends on convenient pharmaceutical formulations ensuring continuity of androgen replacement. Therefore, they must be convenient in usage with a relative independence of medical services. In elderly man, safety of androgen replacement therapy is a concern but in younger subjects (below the age of 50 years) side effects of androgens are usually minimal. For them, long-acting testosterone preparations are well suited. Testosterone implants generate, depending on the dose of implants, 3-6 months of normal plasma testosterone. This method requires minor surgery. Injectable testosterone undecanoate maintains plasma testosterone in the normal range for 12 weeks.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551719     DOI: 10.1007/s00345-003-0364-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  25 in total

1.  Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.

Authors:  H M Behre; K Abshagen; M Oettel; D Hübler; E Nieschlag
Journal:  Eur J Endocrinol       Date:  1999-05       Impact factor: 6.664

2.  Testosterone replacement therapy: something old, something new...

Authors:  E Nieschlag
Journal:  Clin Endocrinol (Oxf)       Date:  1996-09       Impact factor: 3.478

3.  Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.

Authors:  Sigrid von Eckardstein; Eberhard Nieschlag
Journal:  J Androl       Date:  2002 May-Jun

4.  Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men.

Authors:  T Schürmeyer; E Nieschlag
Journal:  Int J Androl       Date:  1984-06

5.  Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate.

Authors:  M Schulte-Beerbühl; E Nieschlag
Journal:  Fertil Steril       Date:  1980-02       Impact factor: 7.329

6.  Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets.

Authors:  M R Zacharin; G L Warne
Journal:  Arch Dis Child       Date:  1997-06       Impact factor: 3.791

7.  Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants.

Authors:  S Kelleher; A J Conway; D J Handelsman
Journal:  Clin Endocrinol (Oxf)       Date:  2001-10       Impact factor: 3.478

8.  Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.

Authors:  H M Behre; S Baus; S Kliesch; C Keck; M Simoni; E Nieschlag
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

9.  Randomized clinical trial of testosterone replacement therapy in hypogonadal men.

Authors:  A J Conway; L M Boylan; C Howe; G Ross; D J Handelsman
Journal:  Int J Androl       Date:  1988-08

10.  Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.

Authors:  F Jockenhövel; E Vogel; M Kreutzer; W Reinhardt; S Lederbogen; D Reinwein
Journal:  Clin Endocrinol (Oxf)       Date:  1996-07       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.